SCHEMBL3717499

SCHEMBL3717499

N#Cc1nc(C(=O)C(N)C(=O)O)c(O)c2c(-c3ccc(Cl)cc3)noc12

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 1/20 0.33
GPBAR1 Q8TDU6 4/20 0.32
CYP2D6 P10635 2/20 0.32
CYP2C9 P11712 2/20 0.32
CYP2C19 P33261 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
DHODH Q02127 2/20 0.31
ADORA2A P29274 1/20 0.31
ADORA1 P30542 1/20 0.31
KDM5A P29375 1/20 0.31
XDH P47989 1/20 0.31
DPP4 P27487 1/20 0.31
DPP7 Q9UHL4 1/20 0.31
EGLN2 Q96KS0 2/20 0.30
EGLN1 Q9GZT9 2/20 0.30
KDM4E B2RXH2 1/20 0.30
NPC1 O15118 1/20 0.30
ALDH1A1 P00352 1/20 0.30
CYP1A2 P05177 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3716789 0.90 TPH1 (0.35) ERBB2MEN1KMT2AADORA2AADORA1
SCHEMBL3722940 0.90 GPBAR1 (0.32) GPBAR1CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL3714390 0.84 DHODH (0.36) GPBAR1CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL3717749 0.84 GPBAR1 (0.38) GPBAR1CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL3717801 0.82 ADORA1 (0.36) ERBB2ADORA2AADORA1EGLN2EGLN1
SCHEMBL2775720 0.80 EGLN1 (0.47) EGLN2EGLN1
SCHEMBL3714404 0.79 ADORA1 (0.39) ADORA2AADORA1XDHEGLN2EGLN1
SCHEMBL3722988 0.74 TPH1 (0.39) GPBAR1KMT2ADHODHEGLN1
SCHEMBL3721279 0.74 EGLN1 (0.39) GPBAR1KMT2AEGLN1KDM4EALDH1A1
SCHEMBL3711503 0.72 PTGS2 (0.40) GPBAR1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2227475-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS Fibrogen, Inc. (US) 2010-09-15 EP disclosed
WO-2009073669-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN, INC. (US) 2009-06-11 WO disclosed